1.89
전일 마감가:
$1.95
열려 있는:
$1.95
하루 거래량:
1.02M
Relative Volume:
1.03
시가총액:
$306.08M
수익:
-
순이익/손실:
$-274.18M
주가수익비율:
-0.7457
EPS:
-2.5346
순현금흐름:
$-198.33M
1주 성능:
+3.28%
1개월 성능:
+15.95%
6개월 성능:
+163.75%
1년 성능:
-87.73%
Neumora Therapeutics Inc Stock (NMRA) Company Profile
명칭
Neumora Therapeutics Inc
전화
(857) 760-0900
주소
260 ARSENAL PLACE, SUITE 1, WATERTOWN
NMRA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
NMRA
Neumora Therapeutics Inc
|
1.89 | 315.79M | 0 | -274.18M | -198.33M | -2.5346 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-09-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2025-04-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
2025-03-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2025-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
2025-03-07 | 다운그레이드 | Stifel | Buy → Hold |
2025-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2024-11-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2024-10-01 | 개시 | H.C. Wainwright | Buy |
2024-07-22 | 개시 | Needham | Buy |
2024-07-08 | 개시 | Mizuho | Outperform |
2023-12-12 | 개시 | Deutsche Bank | Hold |
2023-10-10 | 개시 | BofA Securities | Buy |
2023-10-10 | 개시 | Guggenheim | Buy |
2023-10-10 | 개시 | JP Morgan | Overweight |
2023-10-10 | 개시 | RBC Capital Mkts | Outperform |
2023-10-10 | 개시 | Stifel | Buy |
2023-10-10 | 개시 | William Blair | Outperform |
모두보기
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
Using data models to predict Neumora Therapeutics Inc. stock movement2025 Dividend Review & Real-Time Volume Analysis Alerts - newser.com
Will Neumora Therapeutics Inc. see short term momentum2025 Valuation Update & Fast Moving Stock Trade Plans - newser.com
Neumora Therapeutics' (NMRA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Tools to monitor Neumora Therapeutics Inc. recovery probabilityJobs Report & Community Verified Watchlist Alerts - newser.com
Published on: 2025-10-09 06:47:56 - newser.com
Will Neumora Therapeutics Inc. stock attract more institutional investorsQuarterly Market Summary & Free High Return Stock Watch Alerts - newser.com
Visual analytics tools that track Neumora Therapeutics Inc. performanceTrade Entry Report & High Accuracy Trade Alerts - newser.com
Is Neumora Therapeutics Inc a good long term investmentVolume Weighted Average Price & Rapid Wealth Building Tips - earlytimes.in
Will breakout in Neumora Therapeutics Inc. lead to full recoveryWeekly Profit Report & AI Forecast Swing Trade Picks - newser.com
What insider trading reveals about Neumora Therapeutics Inc. stockQuarterly Market Summary & Stepwise Swing Trade Plans - newser.com
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Neumora Therapeutics Inc. recovery potential after sell offTrade Volume Report & Weekly Return Optimization Alerts - newser.com
Forecasting Neumora Therapeutics Inc. price range with options dataJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
Is Neumora Therapeutics Inc. trending in predictive chart modelsGap Down & Risk Adjusted Buy and Sell Alerts - newser.com
Neumora Therapeutics to Host Virtual R&D Day Highlighting Innovative Therapeutics Pipeline on October 27, 2025 - Quiver Quantitative
Neumora Therapeutics to Host Virtual R&D Day on October 27 - Yahoo Finance
What analysts say about Neumora Therapeutics Inc stockMarket Sentiment Surveys & Start Your Free Trading Journey Today - earlytimes.in
What drives Neumora Therapeutics Inc stock priceEx-Dividend Date Alerts & Minimal Capital Growth Plans - earlytimes.in
Neumora Therapeutics Inc Stock Analysis and ForecastFederal Reserve Announcements & Free Proven Portfolio Growth Strategies - earlytimes.in
Neumora Therapeutics appoints Paul Berns as CEO - MSN
J.P. Morgan Downgrades Neumora Therapeutics(NMRA.US) to Sell Rating - 富途牛牛
Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating - MSN
Following a 85% Decline Over Last Year, Recent Gains May Please Neumora Therapeutics, Inc. (NASDAQ:NMRA) Institutional Owners - 富途牛牛
3 Promising Penny Stocks With Market Caps At Least $100M - simplywall.st
Aug Reactions: Is Neumora Therapeutics Inc benefiting from innovation trendsLong Setup & Weekly Momentum Stock Picks - خودرو بانک
Neumora Therapeutics (NASDAQ:NMRA) Downgraded by JPMorgan Chase & Co. to Underweight - MarketBeat
Market Pulse: Is Neumora Therapeutics Inc. a stock for growth or value investorsTrade Entry Report & Technical Confirmation Alerts - خودرو بانک
Guidance Update: How liquid is Neumora Therapeutics Inc. stockTrade Signal Summary & Stock Market Timing Techniques - خودرو بانک
Neumora Therapeutics Inc (NMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Neumora Therapeutics Inc 주식 (NMRA) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
BERNS PAUL L | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
13,871 |
23,468 |
7,405,004 |
Milligan Michael Lee | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
1,978 |
3,351 |
22,470 |
Aurora Daljit Singh | Chief Strategy Officer |
Feb 18 '25 |
Sale |
1.68 |
8,565 |
14,347 |
88,935 |
Lenz Robert A. | Head of R&D |
Feb 18 '25 |
Sale |
1.67 |
5,614 |
9,383 |
309,092 |
Pinto Joshua | President |
Feb 18 '25 |
Sale |
1.67 |
8,048 |
13,477 |
76,952 |
자본화:
|
볼륨(24시간):